Tislelizumab
Acute Myeloid Leukemia With Positive Minimal Residual Disease
Institute of Hematology & Blood Diseases Hospital, Chinamonoclonal_antibodyPhase 2Active
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 51/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Acute Myeloid Leukemia With Positive Minimal Residual Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pyrotinib SillaJen, Inc. | Phase 2 | B |
rc48-adc SillaJen, Inc. | Phase 2 | B |
Same molecule, other indications
Tislelizumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →